Table 1 Patient characteristics

From: Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients

Factor

n (%)

Total no of patients

64

Age

 Younger than 18 years

8 (12)

 Older than 18 years

56 (88)

 Median (range), years

35 (13-57)

Gender

 Male

39 (61)

 Female

25 (39)

Diagnosis

 AML

29 (45)

 ALL

17 (27)

 CML

6 (9)

 MDS

8 (13)

 Other

4 (6)

Disease risk a

 Standard

52 (81)

 High

12 (19)

Donor type

 Related

45 (70)

 Unrelated

19 (30)

Stem cell source

 PB

50 (78)

 BM

12 (19)

 PB+BM

2 (3)

Conditioning

 Modified BUCY

51 (80)

 Modified BUCY+ATG

13 (20)

GVHD prophylaxis

 CSA+MTX

32 (50)

 CSA+MTX+MMF

32 (50)

  1. Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; BUCY, busulphan+cyclophosphamide; CML, chronic myeloid leukemia; CSA, cyclosporine A; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome; MTX, methotrexate; MMF, mycophenolate mofetil; PB, peripheral blood.
  2. aStandard risk indicates acute leukemia in CR1 or CR2, CML in first chronic phase, MDS without excess blasts or nonmalignant diseases. High risk indicates others.
Back to article page